{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:53:18Z","timestamp":1790351598651,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["V112E-006-2"],"award-info":[{"award-number":["V112E-006-2"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["V113E-006-2"],"award-info":[{"award-number":["V113E-006-2"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["112-2321-B-A49-005-,113-2321-B-A49-011-"],"award-info":[{"award-number":["112-2321-B-A49-005-,113-2321-B-A49-011-"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["114-2321-B-A49-001-"],"award-info":[{"award-number":["114-2321-B-A49-001-"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ijid.2026.108455","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T15:52:47Z","timestamp":1770047567000},"page":"108455","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Clinical outcomes of immunocompromised patients administered tixagevimab\u2013cilgavimab as pre-exposure prophylaxis for COVID-19: Real-world experience in Taiwan"],"prefix":"10.1016","volume":"165","author":[{"given":"Yu-Chien","family":"Ho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Hua","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szu-Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiang-Ling","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9940-7529","authenticated-orcid":false,"given":"Yi-Tsung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2026.108455_bib0001","unstructured":"World Health Organization. Coronavirus disease (COVID-19) https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019. 2024. [accessed 01 September 2024]."},{"key":"10.1016\/j.ijid.2026.108455_bib0002","article-title":"Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study","volume":"35","author":"Evans","year":"2023","journal-title":"Lancet Reg Health Eur"},{"issue":"1","key":"10.1016\/j.ijid.2026.108455_bib0003","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2027160","article-title":"The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review","volume":"18","author":"Mohammed","year":"2022","journal-title":"Hum Vaccin Immunother"},{"issue":"12","key":"10.1016\/j.ijid.2026.108455_bib0004","doi-asserted-by":"crossref","first-page":"271","DOI":"10.15585\/mmwr.mm7312a5","article-title":"Interim effectiveness of updated 2023-2024 (Monovalent XBB.1.5) COVID-19 vaccines against COVID-19-associated hospitalization among adults aged \u226518 years with immunocompromising conditions\u2014VISION network, September 2023-February 2024","volume":"73","author":"Link-Gelles","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"8","key":"10.1016\/j.ijid.2026.108455_bib0005","doi-asserted-by":"crossref","first-page":"e266","DOI":"10.1016\/S1473-3099(23)00357-2","article-title":"Bivalent COVID-19 mRNA vaccine against omicron subvariants in immunocompromised patients","volume":"23","author":"Solera","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.ijid.2026.108455_bib0006","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.annonc.2021.10.014","article-title":"Seroconversion rate after vaccination against COVID-19 in patients with cancer: a systematic review","volume":"33","author":"Corti","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijid.2026.108455_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2022.105217","article-title":"Cellular and humoral immune response to SARS-CoV-2 vaccination and booster dose in immunosuppressed patients: an observational cohort study","volume":"153","author":"Yang","year":"2022","journal-title":"J Clin Virol"},{"issue":"8","key":"10.1016\/j.ijid.2026.108455_bib0008","article-title":"SARS-CoV-2 m-RNA vaccine response in immunocompromised patients: a monocentric study comparing cancer, people living with HIV, hematopoietic stem cell transplant patients and lung transplant recipients","volume":"11","author":"Bordry","year":"2023","journal-title":"Vaccines (Basel)"},{"issue":"7","key":"10.1016\/j.ijid.2026.108455_bib0009","doi-asserted-by":"crossref","first-page":"e250","DOI":"10.1093\/cid\/ciac724","article-title":"Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (September 2022)","volume":"78","author":"Bhimraj","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2026.108455_bib0010","unstructured":"US Food and Drug Administration Coronavirus (COVID-19) update: FDA authorizes new long-acting monoclonal antibodies for pre-exposure prevention of COVID-19 in certain individuals. https:\/\/bit.ly\/3saed1U. 2021. [accessed 16 December 2024]."},{"issue":"23","key":"10.1016\/j.ijid.2026.108455_bib0011","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","article-title":"Intramuscular AZD7442 (Tixagevimab-cilgavimab) for prevention of Covid-19","volume":"386","author":"Levin","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ijid.2026.108455_bib0012","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/cid\/ciac855","article-title":"Effectiveness of Evusheld in immunocompromised patients: propensity score-matched analysis","volume":"76","author":"Najjar-Debbiny","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.ijid.2026.108455_bib0013","doi-asserted-by":"crossref","DOI":"10.1111\/tid.14194","article-title":"Breakthrough SARS-CoV-2 infections among recipients of tixagevimab-cilgavimab prophylaxis: a citywide real-world effectiveness study","volume":"26","author":"Lendacki","year":"2024","journal-title":"Transpl Infect Dis"},{"issue":"12","key":"10.1016\/j.ijid.2026.108455_bib0014","doi-asserted-by":"crossref","first-page":"1654.e1","DOI":"10.1016\/j.cmi.2022.07.015","article-title":"Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients","volume":"28","author":"Nguyen","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"10.1016\/j.ijid.2026.108455_bib0015","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.amjmed.2022.08.019","article-title":"The prevention of COVID-19 in high-risk patients using tixagevimab-cilgavimab (Evusheld): real-world experience at a large academic center","volume":"136","author":"Al-Obaidi","year":"2023","journal-title":"Am J Med"},{"key":"10.1016\/j.ijid.2026.108455_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105417","article-title":"Cilgavimab and tixagevimab as pre-exposure prophylaxis in vaccine non-responder kidney transplant recipients during a period of prevalent SARS-CoV-2 BA.2 and BA.4\/5 variants-a prospective cohort study (RESCUE-TX)","volume":"109","author":"Reindl-Schwaighofer","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ijid.2026.108455_bib0017","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1136\/bmj.p264","article-title":"Covid-19: FDA removes US authorisation for antibody drug Evusheld","volume":"380","author":"Iacobucci","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.ijid.2026.108455_bib0018","unstructured":"US Food and Drug Administration FactSheet for healthcare providers: emergency use authorization of Pemgarda (Pemivibart). https:\/\/www.fda.gov\/media\/177067\/download. 2024. [accessed 15 July 2024]."},{"issue":"Supplement_3","key":"10.1016\/j.ijid.2026.108455_bib0019","doi-asserted-by":"crossref","first-page":"i6","DOI":"10.1093\/cid\/ciae435","article-title":"2024 clinical practice guideline update by the Infectious Diseases Society of America on the management of COVID-19: anti-SARS-CoV-2 neutralizing antibody Pemivibart for pre-exposure prophylaxis","volume":"81","author":"Bhimraj","year":"2026","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2026.108455_bib0020","unstructured":"Taiwan Centers for Disease Control. Guidelines for clinical management of SARS-CoV-2 infection (Traditional Chinese version). https:\/\/www.cdc.gov.tw\/Category\/Page\/xCSwc5oznwcqunujPc-qmQ. 2023. [accessed 15 July 2024]."},{"key":"10.1016\/j.ijid.2026.108455_bib0021","unstructured":"Taiwan Centers for Disease Control. Guidelines for the use of COVID-19 monoclonal antibody combination\u2014Tixagevimab+cilgavimab (Evusheld) (Traditional Chinese version). https:\/\/www.cdc.gov.tw\/Category\/MPage\/rHF_yq4y759vp9ePbg5vag. 2023. [accessed 15 July 2024]."},{"issue":"11","key":"10.1016\/j.ijid.2026.108455_bib0022","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.jfma.2023.05.027","article-title":"Epidemiological characteristics of the three waves of COVID-19 epidemic in Taiwan during April 2022 to March 2023","volume":"122","author":"Chen","year":"2023","journal-title":"J Formos Med Assoc"},{"issue":"3","key":"10.1016\/j.ijid.2026.108455_bib0023","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S1473-3099(23)00010-5","article-title":"ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5","volume":"23","author":"Yue","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"10.1016\/j.ijid.2026.108455_bib0024","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S1473-3099(24)00804-1","article-title":"Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial","volume":"25","author":"Haidar","year":"2025","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.ijid.2026.108455_bib0026","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s40121-025-01124-3","article-title":"Risk of severe COVID-19 in four immunocompromised populations: a French expert perspective","volume":"14","author":"Loubet","year":"2025","journal-title":"Infect Dis Ther"},{"issue":"10475","key":"10.1016\/j.ijid.2026.108455_bib0027","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(24)02560-1","article-title":"Impact of SARS-CoV-2 spike antibody positivity on infection and hospitalisation rates in immunosuppressed populations during the omicron period: the MELODY study","volume":"405","author":"Mumford","year":"2025","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ijid.2026.108455_bib0028","article-title":"Epidemiology and analysis of SARS-CoV-2 Omicron subvariants BA.1 and 2 in Taiwan","volume":"14","author":"Liu","year":"2024","journal-title":"Sci Rep"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971226000901?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971226000901?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T13:30:01Z","timestamp":1778592601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971226000901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":27,"alternative-id":["S1201971226000901"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2026.108455","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical outcomes of immunocompromised patients administered tixagevimab\u2013cilgavimab as pre-exposure prophylaxis for COVID-19: Real-world experience in Taiwan","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2026.108455","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"108455"}}